TORONTO, CANADA — (August 16, 2016) – Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF) today announces that its subsidiary Citagenix Inc. (“Citagenix”) has launched Neomem® FlexPlus, a high-performance barrier membrane for regenerative procedures in oral surgery. Data suggest that Neomem® FlexPlus exceeds performance of a leading barrier membrane in areas that are considered highly important to dental clinicians.

Neomem® FlexPlus is a single layer collagen membrane derived from porcine peritoneum. Suture pull-out testing has shown this membrane to be biomechanically strong yet conformability evaluations demonstrate the ability to adapt to the contour of the surgical site. Neomem® FlexPlus can be placed wet or dry in situ and it hydrates quickly, providing handling characteristics that make surgical placement easy.

Test data and clinical experience suggest that Neomem® FlexPlus outperforms a leading barrier membrane in four metrics, specifically strength, handling, resorption and tissue response.

“The launch of Neomem FlexPlus provides Citagenix with its strongest barrier membrane yet, and a direct competitor to the leading product in the market,” said Dan Legault, Antibe’s CEO. “We see an exciting future for Citagenix and look forward to accelerating growth through new product initiatives and our footprint expansion strategy.”

Neomem® FlexPlus is being sold in Canada through our direct sales force and globally via our network of distribution partners. To learn more about the Neomem® family of products, please visit the product website:

About Antibe Therapeutics Inc.

Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer, non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin.

Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information

This news release includes certain forward-looking statements, which may include, but are not limited to, the growth of product sales, engaging new distributors and independent representatives, the completion of financing transactions and the licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “will”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “propose” and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s ability to secure additional financing, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.

Contact Information

Antibe Therapeutics Inc.
Dan Legault
Chief Executive Officer
Tel: +1 416-473-4095

Read all news


This is an external link. Click “OK” to continue.